FOXO4 Senses Oxidative Stress Through Cysteines and Keeps Senescent Cells Alive via p53

Reactive oxygen species act as signals at low levels and cause damage at high levels, and cells rely on transcription factors to match their antioxidant defenses to the redox state. The FOXO family is a central hub for this. FOXO3 has the strongest link to human longevity, while FOXO4 has been studied far less. FOXO4 matters for two reasons: it directly senses oxidation, and it helps senescent cells resist death, which makes it a possible target for senolytic therapy.

This was a structured narrative review, not a formal systematic review or meta-analysis. The authors searched PubMed/MEDLINE, Scopus and Web of Science through May 2026. Of 420 records, 300 remained after deduplication, 110 full texts were assessed, and 89 publications were retained. Evidence was classified as directly FOXO4-specific (18 papers), FOXO-family or conserved (24), or extrapolated from FOXO1, FOXO3 or DAF-16 (20). A further 27 contextual papers were tracked separately. Only direct FOXO4 evidence was treated as enough for isoform-specific conclusions.

The strongest findings concern mechanism. Oxidation of Cys477 forms a disulfide-dependent complex with p300/CBP, which acetylates FOXO4 and is later reduced by the thioredoxin system. Oxidation of Cys239 or Cys355 forms a disulfide with the import receptor transportin-1, moving FOXO4 into the nucleus; the C. elegans homolog DAF-16 uses the same mechanism. These cysteine switches work alongside Akt/14-3-3 inhibition, JNK phosphorylation at Thr447 and Thr451, SIRT1 deacetylation, and ubiquitination. In senescence, FOXO4 binds p53 and holds it in the nucleus, which blocks p53's pro-apoptotic mitochondrial activity. The D-retro-inverso peptide FOXO4-DRI disrupts this interaction. It selectively kills senescent cells in mice, counteracted chemotoxicity-induced and natural aging features, and in a vascular study lowered ROS and SASP markers and improved aortic function.

In contrast, direct FOXO4 regulation of SOD2, catalase, sestrins, GADD45 and OSER1 is not well demonstrated. These targets come mainly from FOXO3 or pooled FOXO studies, so FOXO4's role is plausible but unproven. Disease roles in cancer, muscle atrophy, cardiometabolic disease and reproductive aging are also graded, and many rest on FOXO-family inference.

FOXO4-DRI should be viewed as an emerging preclinical strategy. Human data from senolytics such as dasatinib plus quercetin cannot be transferred to it. Open questions include tissue selectivity, peptide delivery, pharmacokinetics, long-term toxicity, and whether disrupting p53 handling compromises tumor surveillance. The review calls for isoform-resolved chromatin and transcriptomic studies to define FOXO4's actual target genes.